GUNG-HOPHARMA R&DINVESTMENTSSURPASS $3B While the pharmaceutical industry helped combatCOVID-19, from R&D actions on potential treatmentstrategies to balancing the medicines supply chainin the time of crisis, it struggled to maintain thenatural market flow. As a result, many pharmacompanies had to abort some of their ongoing R&Dinvestment plans. However for FY20-21, the averageR&D expenses constituted 7.2 per cent of the totalrevenues of the pharma companies, with Lupin,Alembic Pharma and Dr. Reddy’s spending morethan others. The cumulative R&D expenditure of theleading 10 pharma companies has been around Rs10,627 crore ($1.43 billion) in the previous fiscal. Thisfigure eventually reaches an approximate amountof Rs 22,500 crore ($3.03 billion) after consideringthe cumulative expenditure by other small andmedium players of the India pharma industry
